Showing results (91-100 of 135) with videos related to

Sort By:
Pageof 14
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|February 21, 2023
Ipilimumab with atezolizumab-bevacizumab in patients with advanced hepatocellular carcinoma: The PRODIGE 81-FFCD 2101-TRIPLET-HCC trialPhilippe Merle, Jean-Frédéric Blanc, Julien Edeline, et al.
Journal of Hepatology|December 13, 2021
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinomaAnn-Lii Cheng, Shukui Qin, Masafumi Ikeda, et al.
Annals of Hepatology|December 26, 2025
Effect of pembrolizumab on viral hepatitis load and transaminases in advanced hepatocellular carcinomaStephen Lam Chan, Richard S Finn, Julien Edeline, et al.
Clinics and Research in Hepatology and Gastroenterology|March 29, 2021
Hepatocellular carcinoma: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, AFEF, SIAD, SFR/FRI)Jean Frédéric Blanc, Audrey Debaillon-Vesque, Gaël Roth, et al.
Journal of Hepatology|June 21, 2019
Toll-like receptor 3 downregulation is an escape mechanism from apoptosis during hepatocarcinogenesisMarc Bonnin, Nadim Fares, Barbara Testoni, et al.
International Journal of Cancer|May 8, 2014
Osteopontin and latent-TGF β binding-protein 2 as potential diagnostic markers for HBV-related hepatocellular carcinomaAndre Nogueira da Costa, Amelie Plymoth, Daniela Santos-Silva, et al.
Liver Cancer|October 30, 2023
Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer Term Follow-Up from the Phase 3 KEYNOTE-240 TrialPhilippe Merle, Masatoshi Kudo, Julien Edeline, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|April 20, 2017
Direct-acting antiviral therapy decreases hepatocellular carcinoma recurrence rate in cirrhotic patients with chronic hepatitis CVictor Virlogeux, Pierre Pradat, Kerstin Hartig-Lavie, et al.
The Lancet. Gastroenterology & Hepatology|June 22, 2026
Addition of ipilimumab to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (PRODIGE 81-FFCD 2101-TRIPLET HCC): phase 2 results from a randomised, multicentre, open-label, phase 2-3 trialPhilippe Merle, Jean-Frederic Blanc, Karine Le Malicot, et al.
Cancer|November 24, 2020
Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE-240Baek-Yeol Ryoo, Philippe Merle, Amit S Kulkarni, et al.
Pageof 14